Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme
The purpose of this study is to determine the safety and effectiveness of Azixa in patients with recurrent glioblastoma multiforme
Glioblastoma Multiforme
DRUG: Azixa
To determine the progression-free survival (PFS) rate, Six 28-day cycles from start of therapy
Overall survival, 36 months|Overall response rate, 18 months
The purpose of this study is to determine the safety and effectiveness of Azixa in patients with recurrent glioblastoma multiforme